???????????????????????????????????????????????????????????????????????BIOFLOW-IV????????????

(PresseBox) - ???????????????????????BIOFLOW-IV????????????????????2???????????????Orsiro????????Xience PRIMETM/ExpeditionTM???????????????????
BIOFLOW-IV????2???????????12???????????????????????????????????????????????? ????12???????29???????????
??????????????????????????????? ???????????? ??????????????????????????????????????????????????IVUS???????????????????????????????????????????????????????????????
???????2011??CE?????????3???????????????????????????????????????????????????????PRO-Kinetic Energy????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????BIOFLOW-I, -II, -III ??????
BIOFLOW-I FIM????????????9????????????????? ???? 0.05±0.22mm???????EuroPCR 2013???????, BIOFLOW-II???????????????????????????????????????????????????????????????? vs. ??????????0.10±0.32mm vs. 0.11±0.29mm?????????????????????????BIOFLOW-III?????????????12????????????4.7%???????????????

????????????????????????????????????????????????????????????5,600???????????100?????????????????????????????????????????1963????????????
????????????????BIOTRONIK???????????????????????????????????????2000????????????????????????????????????????BIOTRONIK Home Monitoring®??2012??????????????????MRI??????????????????????????????????????????BIOTRONIK?50?????????
??????www.biotronik.com????????

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: PresseBox
Datum: 30.10.2013 - 00:30 Uhr
Sprache: Deutsch
News-ID 310607
Anzahl Zeichen: 1530

contact information:
Town:

TOKYO

Kategorie:

Diese Pressemitteilung wurde bisher 271 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"???????????????????????????????????????????????????????????????????????BIOFLOW-IV????????????"
steht unter der journalistisch-redaktionellen Verantwortung von

BIOTRONIK (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event R ...

DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during TCT 2017. Data from ...

TCT 2017: Magmaris Resorbable Magnesium Scaffold (RMS) Continues to Show No Inst ...

Data presented during the TCT congress on BIOTRONIK?s Magmaris1 RMS provide further evidence on its continued safety and efficacy. Pooled 12-month data from the BIOSOLVE-II and BIOSOLVE-III clinical trials highlight high procedural success and the co ...

TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents ...

Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the cas ...

Alle Meldungen von BIOTRONIK